Cell lines

B16 melanoma cell

Preparation method

The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months.

Reacting condition

10 ~ 100 nM; 3 days

Applications

In B16 melanoma cells, Vincristine inhibited the tubulin addition at assembly ends of steady-state microtubules with the Ki value of 85 nM.

Animal models

Mice bearing human rhabdomyosarcoma xenografts Rh12 or Rh18

Dosage form

3 mg/kg; i.p.; a single dose

Applications

In mice bearing human rhabdomyosarcoma xenografts Rh12 or Rh18, Vincristine (3 mg/kg, i.p., a single dose) induced mean growth delay of > 120 and > 52 days, as well as repopulating fractions of 0.06% and 5%, respectively.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Vincristine is a naturally occurring alkaloid that potently inhibits the tubulin addition with the inhibition constant Ki value of 0.085 μM and exhibits an anti-proliferative activity against B16 melanoma cells with the half maximal inhibition concentration IC50 value of 0.45 M [1].

Vincristine is extracted from leaves of the periwinkle plant Catharanthus roseus (L.) G. Don of the family Apocynaceae and has an asymmetric structure consisting of two dimers, a dihydroindole nucleus (vindoline) and an indole nucleus (catharanthine), that are linked by a carbon-carbon bond [2].

Vincristine has been found to be active against a wild range of malignancies, including acute lymphoblastic leukemia (ALL), acute non-lymphoblastic leukemia (ANLL), non-Hodgkin lymphoma (NHL), Hodgkin’s disease and brain tumors [2].

References:
[1] Jordan MA, Himes RH, Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985 Jun;45(6):2741-7.
[2] Gidding CE1, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol. 1999 Feb;29(3):267-87.